Cancer

Title Average Ratingsort ascending
Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice 80.00%
Clinical applications of magnetic nanoparticles for hyperthermia. 80.00%
The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain 80.00%
66 year man. Cholangiocarcinoma 80.00%
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce 80.00%
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. 80.00%
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ 80.00%
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. 80.00%
Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy 80.00%
Regional hyperthermia in high-risk soft tissue sarcomas. 80.00%
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to... 80.00%
Be prudent of ketamine in treating resistant depression in patients with cancer. 80.00%
Newcastle disease virus as an oncolytic agent. 80.00%
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. 80.00%
High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. 80.00%
The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. 80.00%
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt 80.00%
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. 80.00%
Clinical studies of Ukrain in terminal cancer patients (phase II) 80.00%
Clinical experience of integrative cancer immunotherapy with GcMAF. 80.00%
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. 80.00%
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled 80.00%
Complementary and alternative medicines taken by cancer patients 80.00%
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. 80.00%
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. 80.00%
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. 80.00%
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. 80.00%
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocy.. 80.00%
Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour ce 80.00%
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... 80.00%
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma 80.00%
Ukrain therapy of recurrent breast cancer with lung metastases (case report) 80.00%
Melatonin as biological response modifier in cancer patients. 80.00%
Ukrain acts by inhibition of tubulin polymerization in normal and malignant cell lines. 80.00%
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse 80.00%
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) 80.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m 80.00%
Boswellic acids: biological actions and molecular targets. 80.00%
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate ca 80.00%
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. 80.00%
Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice. 80.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine. 80.00%
Bevacizumab for recurrent ependymoma. 80.00%
An Internet misadventure: bloodroot salve toxicity 80.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. 80.00%
Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. 80.00%
The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. 80.00%
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio 80.00%
82 year old woman. Breast cancer with lymph and bone metastasis. 80.00%
Ukrain monotherapy in malignant melanoma (case report) 80.00%
A lipoxygenase inhibitor in breast cancer brain metastases. 80.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer 80.00%
Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. 80.00%
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecula 80.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
Metformin in the treatment of Cancer 77.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. 75.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Cancer Psychotherapy according to Dr. Frederick B Levenson 73.33%
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. 70.00%
Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. 70.00%
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. 70.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. 70.00%
Gastric cancer originating from bone marrow-derived cells. 70.00%
Oncolytic Virus Treatment 70.00%
Photodynamic Therapy 70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r 70.00%
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. 70.00%
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 70.00%
In vitro induction of apoptotic cell death in chronic lymphocytic leukemia by two natural products: preliminary study 70.00%
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. 70.00%
Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. 70.00%
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo 70.00%
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer 70.00%
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. 70.00%
Ukrain treatment in carcinoma of the oesophagus (case report) 70.00%
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi 70.00%
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. 70.00%
Experimental Radiology 70.00%
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. 70.00%
Cancer preventive effect of Morinda citrifolia (Noni). 70.00%
Effects of opioids on the immune system. 70.00%
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. 70.00%
Brain tumour cells killed by anti-nausea drug 70.00%
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer 70.00%
Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells 70.00%
Proton Therapy 70.00%
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline 70.00%
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. 70.00%
Cancer Growth and Its Inhibition in Terms of Coherence 70.00%
Efficacy of ukrain in the treatment of pancreatic cancer. 70.00%
BET bromodomain inhibition as a therapeutic strategy to target c-Myc 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%

Pages